Last reviewed · How we verify
20% dextrose
At a glance
| Generic name | 20% dextrose |
|---|---|
| Also known as | Sweet taste |
| Sponsor | Vanderbilt University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (PHASE1, PHASE2)
- Dexmedetomidine for Invasive Ventilation In the NEOnate (PHASE2, PHASE3)
- Gestational Diabetes and Pharmacotherapy (GAP) (PHASE4)
- Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study (PHASE2)
- Comparative Effects of Periodized Circuit Training and Conventional Strength Training in Patients With Diabetes Type II (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 20% dextrose CI brief — competitive landscape report
- 20% dextrose updates RSS · CI watch RSS
- Vanderbilt University portfolio CI